RIOT

SEC Filing Summary: AspenBio Pharma, Inc. (10-Q)

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for AspenBio Pharma, Inc. for the period ended June 30, 2010. The company is a biopharmaceutical firm focused on developing diagnostic tests (specifically the AppyScore test for appendicitis) and animal health products (BoviPure LH and FSH) under a license with Novartis. The filing notes that the company is a smaller reporting company and a shell company status is denied.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased by 32% ($48,000) compared to the prior six-month period, driven by the timing of customer orders for antigen products.
• Profitability: The company reported a gross profit of $101,739 (51% margin) for the six months ended June 30, 2010, a significant improvement from a gross loss of $(133,850) in the prior year. This was due to a 65% decrease in cost of sales as production of antigen products was suspended to focus on other projects.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by 42% ($1.176 million) due to hiring additional management for clinical trials and increased stock-based compensation ($514,000 increase). Research and development (R&D) expenses decreased by 8% ($303,000) due to lower costs for cassette/reader programs and product studies, partially offset by higher clinical trial costs for the AppyScore test.
• Capital Raise: In May 2010, the company completed a registered direct offering, raising approximately $9.1 million in net proceeds. This significantly improved liquidity compared to the prior period.
• Debt: Total liabilities decreased by approximately $920,000, primarily due to reductions in accounts payable and accrued expenses.

Guidance, Outlook, and Risks

• Outlook: Management believes current working capital is sufficient to fund operations for the near term. The primary focus remains on advancing the AppyScore appendicitis test and single-chain animal health products toward commercialization.
• Capital Expenditures: Anticipated capital expenditures for the remainder of fiscal 2010 are estimated between $100,000 and $300,000, to be financed through working capital.
• Risks:
  • Regulatory Approval: Future success depends on obtaining FDA clearance for the AppyScore test. Failure to achieve this could render prior development costs impaired.
  • Licensing Agreements: The Novartis agreement is contingent on the success of a pilot study expected to complete in 2010. Termination clauses exist for both parties based on performance or regulatory issues.
  • Continued Losses: The company expects to continue incurring losses as it advances product development and regulatory activities.
• Unusual Items: Significant non-cash stock-based compensation of $1.32 million was recorded in the six-month period. A $100,000 milestone was achieved under the Novartis agreement, triggering revenue amortization.

Key Facts for Investor Verification

• Liquidity Position: Verify the sustainability of the $12.5 million cash balance against the burn rate of approximately $6.4 million in operating cash outflows for the six-month period.
• Novartis Pilot Study: Confirm the status and expected completion date of the Novartis pilot study, as its success is a condition for retaining the full license value and future revenue sharing.
• AppyScore Clinical Trial: Review the specific results and FDA submission timeline for the AppyScore appendicitis test, which is the primary driver of R&D spend and future revenue potential.
• Stock-Based Compensation: Assess the impact of the $1.32 million non-cash expense on future cash flow projections and the dilution from the 2.4 million shares and 686,000 warrants issued in May 2010.
• Debt Obligations: Note the mortgage note balance of approximately $2.7 million, with a significant balloon payment of ~$1.59 million due in June 2013.